Luye Pharma Announces Innovative Drug - Risperidone Extended Release Microspheres for Injection has Reached Final Stage of NDA Process
SHANGHAI, Dec. 30, 2018
SHANGHAI, Dec. 30, 2018 /PRNewswire/ -- Luye Pharma Group, an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications, today announced that it has entered the final stage of New Drug Application (NDA) submissions for the innovative drug, Risperidone Extended Release Microspheres for Injection ('LY03004), after previous positive pre-NDA meeting with the U.S. Food and Drug Administration (FDA) and subsequent related procedures.
Luye Pharma had previously requested an NDA number for LY03004 and received a Pre-Assigned NDA application number (212849) from the FDA in 2018. The submission dossier for LY03004 is completed and being published in eCTD format according to FDA requirements.
Luye Pharma successfully reached an agreement with the FDA to waive all paediatric clinical studies of LY03004, and obtained FDA's approval of using Rykindo® as LY03004's brand name for the treatment of Schizophrenia or Schizoaffective Disorder.
A senior managing representative at Luye Pharma Group commented: "We have been working diligently on the submission packages, assembling the regulatory, clinical, nonclinical, and most recently, CMC components of LY03004, and plan to submit the formal NDA soon. We expect LY03004 will be launched in the U.S. and China markets by the end of 2019."
In addition to LY03004, Luye Pharma has numerous pipeline projects targeting the central nervous system therapeutic area, for development both in the U.S and European markets, with projects such as Rotigotine extended release microspheres for injection (LY03003) for Parkinson's disease, Ansofaxine Hydrochloride extended release tablets (LY03005) for anti-depression, Rivastigmine multi-day transdermal patch (30410) for mild to moderate Alzheimer's disease, and Paliperidone Palmitate injectable suspension for intramuscular use (LY03010). Moreover, registration of Rivastigmine single-day transdermal patch has already been accepted by National Medicine Products Administration in China.
The registrations of above products are progressing well in strategic markets such as China, the U.S., Europe and Japan, expecting to launch in these countries and further expand into the global market.
About Luye Pharma Group
Luye Pharma Group is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications. The company has established R&D centers in China, the U.S. and Europe, with a robust pipeline of more than 30 drug candidates in China and more than 10 drug candidates overseas. The company currently has a number of new drugs and new formulations in the central nervous system and oncology therapeutic areas under study in the U.S. and Europe. Luye Pharma has reached a high level international standard in advanced drug delivery technologies such as microspheres, liposomes and transdermal drug delivery systems. The company is forward looking, with strategic development of innovative new compounds and antibodies, gene & cell therapies and smart formulations.
Luye Pharma has set up 7 manufacturing sites with over 30 production lines in total, establishing GMP quality management and international standard control systems. The company offers more than 30 products covering the 4 largest and fastest growing therapeutic areas -- oncology, cardiovascular, metabolism and central nervous system, with business conducted in over 80 countries and regions around the world, including the largest pharmaceutical markets - China, the U.S., Europe and Japan, as well as fast growing emerging markets.
View original content:http://www.prnewswire.com/news-releases/luye-pharma-announces-innovative-drug---risperidone-extended-release-microspheres-for-injection-has-reached-final-stage-of-nda-process-300771387.html
SOURCE Luye Pharma Group